Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (9875)	2/20/2018 2:17:48 PM
From: donpat	2 Recommendations Recommended By drkaz hpgrant Read Replies (2) \| Respond to of 12873

Carolyn Myers, M.B.A., Ph.D. Dr. Myers is an accomplished pharmaceutical executive with extensive experience optimizing productivity, creating value and increasing profitability. She has broad general management, business development and commercial expertise in US and global markets, and is adept at developing strategic plans and translating them into actionable objectives that drive performance and growth. In her most recent position as Vice President, Global Alliance Management & International Brand Business Development at Allergan (NYSE: AGN), Dr. Myers led an Alliance Management team that managed over 150 partners, representing a sizeable portion of Allergan’s promoted and development product portfolio. In her BD role, she led development of ex-US business development strategy, and directed the evaluation and ultimate negotiation of business development opportunities. Earlier, Dr. Myers was Vice President, CNS Marketing at Forest Laboratories (acquired by Allergan in 2015), where she managed the marketing team responsible for CNS brands with $2.5B in annual sales (about 75% of company revenue in 2011). She directed the creation and execution of brand strategies and tactics for marketed brands, for new product launches and for brands in development. Before joining Allergan, Dr. Myers was President at Dey Laboratories, Mylan’s branded business unit, which had about $580M in sales and more than 300 employees. She managed the entire business unit, including strategic and long-range planning, sales and marketing, clinical development, manufacturing and distribution. During her tenure, she achieved EBITDA growth of 80% in 2009, 28% in 2010 and 26% in 2011. Previously, she was President of Mylan Technologies, a developer and manufacturer of generic and branded transdermal products. She led the prioritization of the drug development pipeline, which ultimately led to FDA approval of three key transdermal products, and directed various BD deals, including licensing the EMSAM® patch to Bristol-Myers Squibb. She also was Vice President, Business Development & Strategic Marketing, working with senior leadership to enhance Mylan’s branded business strategy. She is a member of Mid Atlantic Bio Angels, a member of AAAS and a board member at the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. http://www.bioensemble.com/about.html

To: donpat who wrote (9875)	2/20/2018 2:37:05 PM
From: donpat	2 Recommendations Recommended By drkaz hpgrant Read Replies (2) \| Respond to of 12873

Seymour resigned Subsequent event: Effective January 27, 2018 the Company’s Chief Executive Officer, Dr. Eugene Seymour, resigned as the Chief Executive Officer and as a Director of the Company to allow a successor with pharmaceutical experience to serve in this capacity. Subject to the entry into a Severance Agreement, Dr. Seymour will assume the role of Chief Executive Officer Emeritus. The Board of Directors commenced a search for a permanent replacement for Dr. Seymour, which is ongoing. Pending the appointment of a permanent Chief Executive Officer, the Board of Directors appointed Dr. Anil Diwan, the Company’s President, as interim Chief Executive Officer. As of the date of this report, the Company and Dr. Seymour have not yet entered into a Severance Agreement. The Company is now actively looking for a CEO with pharmaceutical industry novel chemical entity drug development experience to lead us to our next stage, namely clinical development and, assuming success in the clinic, further commercialization of our drugs. The Company has begun the interview process for the next CEO. However, interviewing multiple candidates, due diligence, selection and offer to a candidate, and the contractual paperwork may take some time to complete. Meanwhile, the Company’s progress is expected to continue unaffected by the loss of the previous CEO, with Dr. Diwan, who has served as the Company’s President since 2005, assuming additional duties as interim CEO. Dr. Diwan has been performing several of the CEO duties increasingly since the 2013 uplisting from the OTC Markets to our NYSE listing. Dr. Diwan was instrumental in the design, development, and financing of our modern, state of the art nanomedicines synthesis, characterization, and production facility. Further, Dr. Diwan led several of the Company’s financing efforts with Dr. Seymour including two registered direct offerings conducted in September 2013 and January 2014 respectively, that raised approximately $30 million. secinfo.com

To: donpat who wrote (9875)	2/25/2018 9:09:04 PM
From: donpat	Read Replies (1) \| Respond to of 12873

In re Carolyn Myers Mylan Laboratories Appoints Carolyn Myers, Ph.D., President of Mylan Technologies Inc. PRNewswire-FirstCall PITTSBURGH Mylan Laboratories Inc. (NYSE: MYL) today announced the promotion of Carolyn Myers, Ph.D., to the position of President of Mylan Technologies Inc. (MTI), the company's subsidiary that develops, manufactures and distributes transdermal drug delivery systems and related technologies. (Photo: newscom.com Dr. Myers has spent more than 16 years in both domestic and international pharmaceutical brand management and has led a number of product launches in primary care and specialty markets. She joined Mylan in 2003 as Vice President of Branded Business Development and Strategic Marketing. In this role, Dr. Myers led the successful execution of multiple projects including the strategic alliance for the outlicensing of nebivolol. Dr. Myers earned a Ph.D. in molecular genetics from the University of British Columbia and an MBA from Rutgers, The State University of New Jersey. Sharad Govil, Ph.D., Vice President of Mylan Laboratories, who had been serving as President of MTI will be expanding his responsibilities at the holding company. Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer, stated, "Carolyn Myers is an extremely talented executive and is well positioned to lead our strategic initiatives for Mylan Technologies going forward. Mylan has already benefited significantly from her scientific background, deep branded and generic industry experience, leadership and vision. We view Mylan Technologies as a key asset that will play an integral part of our growth strategy going forward, and Carolyn will lead our efforts to fully maximize strategic alliances and other potential opportunities for MTI." Dr. Myers commented, "Since joining Mylan in 2003, I have had the opportunity to lead multiple successful branded and generic initiatives including strategic alliances and other opportunities that have played a role in establishing Mylan Technologies as a leading force in the transdermal market. We believe there are significant unmet medical needs in multiple therapeutic categories that transdermal technology can address, and MTI is uniquely positioned to address these needs based on its industry-leading capabilities and proven track record of success. I am very excited to lead MTI in the pursuit of continued innovation and success in the rapidly growing transdermal market." Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, visit www.mylan.com. This press release includes statements that constitute "forward-looking statements," including with regard to anticipated continued success, growth and strategic opportunities for MTI. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding market acceptance of, and demand for, products; unexpected regulatory or other delays; the effects of vigorous competition on commercial acceptance of products and their pricing; the inability to reach mutually agreeable contract terms with potential strategic partners; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Photo: NewsCom: newscom.com AP Archive: photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com SOURCE: Mylan Laboratories Inc. CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc., +1-724-514-1800 Web site: mylan.com newsroom.mylan.com biospace.com bloomberg.com